In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Comparison of the effect of valsartan, eprosartan or losartan on N-terminal pro-brain natriuretic peptide plasma level and diastolic function in essential hypertension

Session Poster Session 5

Speaker Liuba Popescu

Event : ESC Congress 2018

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Diseases: Biomarkers
  • Session type : Poster Session

Authors : LT Popescu (Chisinau,MD), A P Caraus (Chisinau,MD)

L.T. Popescu1 , A.P. Caraus1 , 1Institute of Cardiology, hypertension - Chisinau - Moldova Republic of ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 996

Background: The epidemiological studies have confirmed that half of patients with heart failure indeed have preserved ejection fraction. Hypertension is one of the common causes of diastolic dysfunction and heart failure. Early treatment is important in preventing irreversibile structural alterations and systolic dysfunction.

Objective: To compare the effects of an angiotensin receptor blockers - in a based regimen on valsartan, eprosartan or losartan on diastolic function and N-terminal pro-brain natriuretic peptide levels in heart failure with preserved left ventricular ejection fraction.

Methodology: In this study were included 165 hypertensive patients with a systolic blood pressure ≥140 mmHg, a left ventricular ejection fraction ≥50% and diastolic dysfunction. Echocardiographic indices derived from Doppler mitral inflow velocities, combined with tissue Doppler imaging, where E1/A1 ratio was (0,37±0,02) and E/A ratio was (0,61±0,01), confirmed the diastolic dysfunction with impaired relaxation profile. The plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) were ≥125 pg/ml for all patients in the study. All patients were randomly selected for treatment with valsartan, eprosartan or losartan for a period of 30 months. At baseline and at the end of the 30 months of treatment, echocardiography, ambulatory blood pressure monitoring and NT-proBNP assessments were performed.

Results: Although ambulatory blood pressure levels, echocardiographic diastolic parameters and plasma levels of NT-proBNP did not differ significantly between groups at baseline, after treatment period, such measurements as systolic blood pressure levels were lower (-28,5%, p<0,001) in eprosartan group, versus valsartan and losartan (-25,8% and -23,9%, respectively, p<0,01). E/E1 ratio was also lower in eprosartan group (-30%, p<0,001) than valsartan or losartan groups. The NT-proBNP levels were decresed in all study groups, but while in eprosartan group the levels were -45,6%, p<0,001, in valsartan or losartan groups the levels were similar: -28,9% and -26,5%, respectively, p<0,01. We noticed a medium negative relatioship between E1/A1 ratio and average mean systolic blood pressure (r=-0,48, p<0,01).

Conclusion: At the end of the study, after 30 months of therapy with valsartan, eprosartan or losartan, a significant improvement was noted in all diastolic function variables, in patients with preserved left ventricular ejection fraction. Eprosartan treatment resulted in a more significant reduction in levels of NT-proBNP and systolic blood pressure. At the end of follow-up period, the proportion of patients achieving normalization of blood pressure was higher with eprosartan versus valsartan or losartan (96% versus 85,4% or 79,2%, p<0,0001, x2=46,1), this difference did achieve statistical significance.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are